摘要
目的利用生物信息学方法对羊布鲁氏菌Omp25蛋白进行分析,预测其T细胞以及B细胞的优势抗原表位。方法从NCBI数据库中获取羊布鲁氏菌的Omp25蛋白的氨基酸序列。应用ProtParam在线软件分析Omp25蛋白的理化性质,应用SOMPA在线软件分析Omp25蛋白二级结构,应用Phyre2及SWISS-MODEL在线软件构建并分析Omp25蛋白三级结构,应用ABCpred和BepiPred等在线软件预测Omp25蛋白的B细胞抗原表位,应用SYFPEITHI和IEDB在线软件预测Omp25蛋白的T细胞抗原表位。结果Omp25蛋白含有23个强碱性氨基酸,含有21个强酸性氨基酸,归类为亲水性稳定蛋白,Omp25蛋白的二级结构中α-螺旋占24.88%,β-折叠占25.35%,β-转角占2.82%,无规则卷曲占46.95%。联合不同软件的预测结果分析后,最终获得1段CD4^+T细胞优势抗原表位、3段CD8^+T细胞优势抗原表位以及3段B细胞优势抗原表位。结论通过生物学信息的方法较为全面地预测了羊布鲁氏菌Omp25蛋白的优势T细胞以及B细胞抗原表位,为进一步研制羊布鲁氏菌表位疫苗构建提供了理论基础。
Objective To analyze the epitope of Omp25 protein from Brucella mutans using bioinformatics methods,thereby understanding its physicochemical properties and the second and third grade structure of proteins.MethodsThe amino acid sequence of the Omp25 protein of Brucella mutans was obtained from the NCBI database.The physical and chemical properties of Omp25 protein were analyzed by ProtParam online software;the secondary structure of Omp25 protein was analyzed by SOMPA online software;the tertiary structure of Omp25 protein was constructed and analyzed by Phyre2 and SWISS-MODEL online software.ResultsOmp25 protein contains 23 strong basic amino acids containing 21 strongly acidic amino acids,which was classified as hydrophilic stable proteins.The ids containine secondary structure of Omp25 protein accounts for 24.88%,andβ-fold accounts for 25.35%.β-the corner accounts for 2.82%and the irregular curl accounted for 46.95%.After analysis of the predicted results using different softwares,the first dominant CD4^+T cell epitope,the third CD8^+T cell dominant epitope and the third B cell dominant epitope were obtained.ConclusionThe method of biological information comprehensively predicts the dominant T cells and B cell epitopes of Brucella obesity Omp25 protein,thus providing a theoretical basis for further development of Brucella epidermal vaccine construction.
作者
陈志强
沙桐
李智伟
丁剑冰
张峰波
CHEN Zhiqiang;SHA Tong;LI Zhiwei;DING Jianbing;ZHANG Fengbo(Department of Immunology, Basic Medical College, Xinjiang Medical University, Urumqi 830011, China;Clinical Laboratory Center, People′s Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China;Department of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China)
出处
《新疆医科大学学报》
CAS
2020年第4期414-418,共5页
Journal of Xinjiang Medical University
基金
国家自然科学基金(81860352,81560322,81860375)
新疆维吾尔自治区自然科学基金(2018D01C094)
新疆维吾尔自治区人民医院科技引进创新项目(20180216)。